We've launched a new site so please go to People & Research for current information on our faculty and staff.

Syed Y. Zafar, Associate Professor of Medicine, Medical Oncology and Sanford School of Public Policy and Affiliate, Duke Global Health Institute of Duke Global Health Institute and Member of Duke Cancer Institute and Duke Clinical Research Institute  

Office Location: Seeley G. Mudd Building, Rm 43, 10 Bryan Searle Dr., DUMC 3505, Durham, NC 27710
Office Phone: (919) 684-8111
Duke Box: 3505
Email Address: yousuf.zafar@duke.edu
Twitter: https://twitter.com/yzafar

Areas of Expertise

    M.D., University of Toledo, 2002

    Representative Publications   (More Publications)

    1. Zafar, SY; Malin, JL; Grambow, SC; Abbott, DH; Kolimaga, JT; Zullig, LL; Weeks, JC; Ayanian, JZ; Kahn, KL; Ganz, PA; Catalano, PJ; West, DW; Provenzale, D. "Chemotherapy use and patient treatment preferences in advanced colorectal cancer: A prospective cohort study." Cancer 119.4 (2013): 854-862. [22972673], [doi]  [abs]
    2. Uronis, HE; Bendell, JC; Altomare, I; Blobe, GC; Hsu, SD; Morse, MA; Pang, H; Zafar, SY; Conkling, P; Favaro, J; Arrowood, CC; Cushman, SM; Meadows, KL; Brady, JC; Nixon, AB; Hurwitz, HI. "A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.." The Oncologist 18.3 (January, 2013): 271-272. [23485624], [doi]  [abs]
    3. Zafar, SY; Abernethy, AP. "Financial toxicity, Part I: a new name for a growing problem.." Oncology (Williston Park, N.Y.) 27.2 (2013): 80-149. [23530397]
    4. Zafar, SY; Peppercorn, JM; Schrag, D; Taylor, DH; Goetzinger, AM; Zhong, X; Abernethy, AP. "The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.." The Oncologist 18.4 (January, 2013): 381-390. [23442307], [doi]  [abs]
    5. Phelan, SM; Griffin, JM; Jackson, GL; Zafar, SY; Hellerstedt, W; Stahre, M; Nelson, D; Zullig, LL; Burgess, DJ; Ryn, MV. "Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer." Psycho Oncology 22.1 (2013): 65-73. [21954081], [doi]  [abs]
    6. Strickler, JH; Starodub, AN; Jia, J; Meadows, KL; Nixon, AB; Dellinger, A; Morse, MA; Uronis, HE; Marcom, PK; Zafar, SY; Haley, ST; Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.." Cancer Chemother Pharmacol 70.2 (August, 2012): 251-258. [22744359], [doi]  [abs]
    7. Vlahovic, G; Meadows, KL; Uronis, HE; Morse, MA; Blobe, GC; Riedel, RF; Zafar, SY; Alvarez-Secord, A; Gockerman, J; Starodub, AN; Ready, NE; Anderson, EL; Bendell, JC; Hurwitz, HI. "A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.." Cancer Chemotherapy and Pharmacology 70.1 (July, 2012): 95-102. [22638798], [doi]  [abs]
    8. Palta, M; Patel, P; Broadwater, G; Willett, C; Pepek, J; Tyler, D; Zafar, SY; Uronis, H; Hurwitz, H; White, R; Czito, B. "Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.." Annals of Surgical Oncology 19.5 (May, 2012): 1535-1540. [22045467], [doi]  [abs]
    9. Currow, DC; Tieman, JJ; Greene, A; Zafar, SY; Wheeler, JL; Abernethy, AP. "Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research.." Journal of Pain and Symptom Management 43.5 (May, 2012): 902-910. [22445274], [doi]  [abs]
    10. Rangwala, F; Zafar, SY; Abernethy, AP. "Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.." Current Opinion in Supportive and Palliative Care 6.1 (March, 2012): 69-76. [22228030], [doi]  [abs]
    11. Zafar, SY; Currow, DC; Cherny, N; Strasser, F; Fowler, R; Abernethy, AP. "Consensus-based standards for best supportive care in clinical trials in advanced cancer.." The Lancet. Oncology 13.2 (February, 2012): e77-e82. [22300862], [doi]  [abs]
    12. Zafar, SY; Malin, JL; Grambow, SC; Abbott, DH; Schrag, D; Kolimaga, JT; Zullig, LL; Weeks, JC; Fouad, MN; Ayanian, JZ; Wallace, R; Kahn, KL; Ganz, PA; Catalano, P; West, DW; Provenzale, D; Cancer Care and Outcomes Research and Surveillance (CanCORS) Consortium,. "Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.." Bmc Cancer 11 (August, 2011): 354. [21846341], [doi]  [abs]
    13. Bullock, KE; Petros, WP; Younis, I; Uronis, HE; Morse, MA; Blobe, GC; Zafar, SY; Gockerman, JP; Lager, JJ; Truax, R; Meadows, KL; Howard, LA; O'Neill, MM; Broadwater, G; Hurwitz, HI; Bendell, JC. "A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).." Cancer Chemotherapy and Pharmacology 67.2 (February, 2011): 465-474. [21079958], [doi]  [abs]
    14. Zafar, SY; Currow, DC; Daugherty, CK; Abernethy, AP. "Standards for palliative care delivery in oncology settings.." Cancer Journal 16.5 (September, 2010): 436-443. [20890139], [doi]  [abs]
    15. Currow, DC; Foley, K; Zafar, SY; Wheeler, JL; Abernethy, AP. "The need for a re-evaluation of best supportive care studies reported to date.." British Journal of Cancer 104.3 (February, 2011): 390-391. [21285970], [doi]
    16. Altomare, I; Bendell, JC; Bullock, KE; Uronis, HE; Morse, MA; Hsu, SD; Zafar, SY; Blobe, GC; Pang, H; Honeycutt, W; Sutton, L; Hurwitz, HI. "A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.." The Oncologist 16.8 (January, 2011): 1131-1137. [21795432], [doi]  [abs]
    17. Hirsch, BR; Zafar, SY. "Capecitabine in the management of colorectal cancer.." Cancer Management and Research 3 (January, 2011): 79-89. [21629830], [doi]  [abs]
    18. Abernethy, AP; Aziz, NM; Basch, E; Bull, J; Cleeland, CS; Currow, DC; Fairclough, D; Hanson, L; Hauser, J; Ko, D; Lloyd, L; Morrison, RS; Otis-Green, S; Pantilat, S; Portenoy, RK; Ritchie, C; Rocker, G; Wheeler, JL; Zafar, SY; Kutner, JS. "A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group.." Journal of Palliative Medicine 13.12 (December, 2010): 1407-1413. [21105763], [doi]  [abs]
    19. Abernethy, AP; Zafar, SY; Uronis, H; Wheeler, JL; Coan, A; Rowe, K; Shelby, RA; Fowler, R; Herndon, JE. "Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.." Journal of Pain and Symptom Management 40.4 (October, 2010): 545-558. [20579839], [doi]  [abs]
    20. Bull, J; Zafar, SY; Wheeler, JL; Harker, M; Gblokpor, A; Hanson, L; Hulihan, D; Nugent, R; Morris, J; Abernethy, AP. "Establishing a regional, multisite database for quality improvement and service planning in community-based palliative care and hospice.." Journal of Palliative Medicine 13.8 (August, 2010): 1013-1020. [20649439], [doi]  [abs]
    21. Jackson, GL; Melton, LD; Abbott, DH; Zullig, LL; Ordin, DL; Grambow, SC; Hamilton, NS; Zafar, SY; Gellad, ZF; Kelley, MJ; Provenzale, D. "Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs.." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28.19 (July, 2010): 3176-3181. [20516431], [doi]  [abs]
    22. Abernethy, AP; Ahmad, A; Zafar, SY; Wheeler, JL; Reese, JB; Lyerly, HK. "Electronic patient-reported data capture as a foundation of rapid learning cancer care.." Medical Care 48.6 Suppl (June, 2010): S32-S38. [20473201], [doi]  [abs]
    23. SY Zafar, JE Marcello, JL Wheeler, KL Rowe, MA Morse, JE Herndon 2nd, AP Abernethy. "Treatment-related toxicity and supportive care in metastatic colorectal cancer.." The journal of supportive oncology 8.1 (April, 2010): 15-20.  [abs]
    24. Abernethy, AP; Wheeler, JL; Zafar, SY. "Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.." Current Opinion in Supportive and Palliative Care 4.1 (March, 2010): 36-45. [19952928], [doi]  [abs]
    25. Chrischilles, EA; Pendergast, JF; Kahn, KL; Wallace, RB; Moga, DC; Harrington, DP; Kiefe, CI; Weeks, JC; West, DW; Zafar, SY; Fletcher, RH. "Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28.4 (February, 2010): 620-627. [20038726], [doi]  [abs]
    26. Cherny, NI; Abernethy, AP; Strasser, F; Sapir, R; Currow, D; Zafar, SY. "Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review.." Journal of Clinical Oncology 27.32 (November, 2009): 5476-5486. [19564538], [doi]  [abs]
    27. Zafar, SY; Marcello, JE; Wheeler, JL; Rowe, KL; Morse, MA; Herndon, JE; Abernethy, AP. "Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.." Journal of Oncology Practice 5.5 (September, 2009): 228-233. [20856733], [doi]  [abs]
    28. A Dupont, J Wheeler, JE Herndon 2nd, A Coan, SY Zafar, L Hood, M Patwardhan, HS Shaw, HK Lyerly, AP Abernethy. "Use of tablet personal computers for sensitive patient-reported information.." The journal of supportive oncology 7.3 (August, 2009): 91-7.  [abs]
    29. Abernethy, AP; Barbour, SY; Uronis, H; Zafar, SY; Coan, A; Rowe, K; Pupa, MR; Wheeler, JL; Herndon, JE. "Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.." Supportive Care in Cancer 17.6 (June, 2009): 735-744. [19096882], [doi]  [abs]
    30. Abernethy, AP; Wheeler, JL; Zafar, SY. "Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach.." Current Opinion in Supportive and Palliative Care 3.1 (March, 2009): 41-49. [19365160], [doi]  [abs]
    31. Zafar, SY; Alexander, SC; Weinfurt, KP; Schulman, KA; Abernethy, AP. "Decision making and quality of life in the treatment of cancer: a review.." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 17.2 (February, 2009): 117-127. [18802727], [doi]  [abs]
    32. Zafar, SY; Currow, D; Abernethy, AP. "Defining best supportive care.." Journal of Clinical Oncology 26.31 (November, 2008): 5139-5140. [18838696], [doi]
    33. Zafar, SY; Howell, DN; Gockerman, JP. "Malignancy after solid organ transplantation: an overview.." The Oncologist 13.7 (July, 2008): 769-778. [18614590], [doi]  [abs]
    34. Zafar, SY; Abernethy, AP; Abbott, DH; Grambow, SC; Marcello, JE; Herndon, JE; Rowe, KL; Kolimaga, JT; Zullig, LL; Patwardhan, MB; Provenzale, DT. "Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.." Bmc Cancer 8.1 (November, 2008): 345. [19032772], [doi]  [abs]

    Dr. Zafar is a health services researcher with a focus in improving care delivery for patients with advanced cancer. He has obtained advanced training in health services research and has participated in single-institution, multi-institution and national studies focusing on access to care, cost of care, and comparative effectiveness of care delivery between health systems. His primary area of interest is in the cost of cancer care. He has conducted institutional and national studies on how treatment-related costs impact cancer patients' experience. His current work in this arena is focused on patient preferences regarding cost-related communication and decision-making.

    A second field of interest is palliative care. Dr. Zafar has collaborated with national and international palliative care leaders to improve the design and delivery of palliative care in cancer clinical trials. Methodologically, this work has centered around systematic literature reviews, iterative surveys, and prospective clinical trials.

    Dr. Zafar is a member of the American Society of Clinical Oncology’s Health Disparities and Clinical Practice Guideline Committees. He is a member of the Alliance for Clinical Trials in Oncology's Health Disparities and Health Outcomes Committees. Dr. Zafar's work has been funded by the American Cancer Society, the HealthWell Foundation, the Duke Cancer Prevention and Control Program, the Duke Clinical Research Institute, and the CALGB Foundation.

    Syed Y. Zafar